Lack of OHE-specific diagnostic code in hospitals may increase risk of additional cost, length of hospitalization and additional burdens for patients compared to those with a previous primary OHE diagnosisLAVAL, QC /

BHC

WiSA Technologies Announces Pricing Of $4.8M Public Offering Of Series B Convertible Redeemable Preferred Stock And Warrants

By Benzinga Newsdesk

October 16, 1:31 PM

WiSA Technologies, Inc. (NASDAQ:WISA), a developer of spatial, wireless sound technology for smart devices and next-generation home entertainment systems, today announced the pricing of a public offering of 87,000 units

WISA

M&A
News

Standard General Acquisition Of TEGNA Receives Approval From Team Telecom

By Michael Horton

November 18, 5:33 PM

Standard General L.P. ("Standard General") and TEGNA Inc. (NYSE:TGNA) today announced that the National Telecommunications and Information Administration, on behalf of the Committee for the Assessment of

TGNA

BTIG Downgrades Magenta Therapeutics to Neutral

Related Posts

Goldman Sachs Maintains Buy Rating for PDD Holdings: Here’s What You Need To Know

The Absence Of An Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result In Increased OHE-Related Length Of Stay And Hospitalization-Related Costs Due To OHE Rate Underestimation, According To New Analysis

WiSA Technologies Announces Pricing Of $4.8M Public Offering Of Series B Convertible Redeemable Preferred Stock And Warrants

Standard General Acquisition Of TEGNA Receives Approval From Team Telecom